Skye Completes 26-week Treatment Phase in Phase 2a CBeyond(TM) Study

Stock Information for Skye Bioscience Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Skye Bioscience Inc.

Skye Bioscience and Redx Pharma Announce Transaction Agreement and $125 Million in Financings
Skye Announces Cohort Review Committee Approved Opening of Cohort 2 Based on Favorable Safety Data from First Four Participants Treated in Cohort 1
UPDATE - Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update
Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update
Kuehn Law Encourages Investors of Skye Bioscience, Inc. to Contact Law Firm
Skye Bioscience Presenting at GLP-1-Based Therapeutics Summit
Skye Bioscience Treats First Patient in Nimacimab Higher-Dose Expansion Study Evaluating Exposure-Response to Inform Phase 2b Dose Selection for GLP-1 Combination Development
Skye Bioscience Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.